Professor Charles L. Sawyers, professor at Memorial Sloan-Kettering Cancer Center has been named the recipient of the 2017 Scheele Award with the following motivation: “For his outstanding contribution in life science. Professor Sawyers’s work has led to insights into the molecular mechanisms that cause tumor resistance to cancer drugs which have paved the way for the development of new, effective treatments have led to increased survival for many patients.”
The Swedish Academy of Pharmaceutical Sciences has biannually bestowed the Scheele Award in the honor of the world-renowned Swedish chemist and pharmacist Carl Wilhelm Scheele.
In the American scientific journal PNAS (Proceedings of the National Academy of Science), Professor Sawyer was described with the words; ”… a rock star in his own right.” ”…The unlikely assemblage of rock star and researcher shined the spotlight on pioneering efforts in translational cancer research. Few physicians deserve that spotlight more than Sawyers, who co-discovered the targeted cancer drug, Gleevec, forging a path to cancer treatment that has now become increasingly common.”
At Sprint Bioscience, we agree and congratulate Professor Sawyer to the Scheele Award!
Sprint Bioscience work continues in the footsteps of Professor Sawyer’s by developing cancer drugs with new principles of treatment and a targeted mechanism of action.
Read more about the Scheele Award here.
